Zacks Research Estimates Chemours’ FY2024 Earnings (NYSE:CC)

The Chemours Company (NYSE:CC) – Research analysts at Zacks Research lowered their FY2024 earnings per share estimates for Chemours in a research note issued to investors on Tuesday, January 14th. Zacks Research analyst R. Department now expects that the specialty chemicals company will post earnings per share of $1.20 for the year, down from their previous estimate of $1.28. The consensus estimate for Chemours’ current full-year earnings is $1.21 per share. Zacks Research also issued estimates for Chemours’ Q1 2026 earnings at $0.61 EPS.

Other equities research analysts have also recently issued reports about the stock. Morgan Stanley decreased their target price on shares of Chemours from $25.00 to $22.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Mizuho decreased their price target on shares of Chemours from $22.00 to $21.00 and set a “neutral” rating on the stock in a report on Tuesday, January 7th. BMO Capital Markets upped their price objective on Chemours from $30.00 to $32.00 and gave the stock an “outperform” rating in a report on Monday, October 7th. Royal Bank of Canada reiterated an “outperform” rating and issued a $25.00 target price on shares of Chemours in a report on Thursday, December 12th. Finally, Barclays boosted their price target on Chemours from $21.00 to $23.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 5th. Five research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Chemours has a consensus rating of “Hold” and a consensus target price of $23.75.

Chemours Stock Up 1.7 %

Shares of NYSE:CC opened at $19.41 on Friday. The company has a current ratio of 1.73, a quick ratio of 0.92 and a debt-to-equity ratio of 6.05. The firm has a market cap of $2.90 billion, a price-to-earnings ratio of 38.82 and a beta of 1.83. The stock’s 50-day moving average price is $19.13 and its two-hundred day moving average price is $19.77. Chemours has a 12-month low of $15.10 and a 12-month high of $32.48.

Chemours (NYSE:CC) last released its quarterly earnings results on Monday, November 4th. The specialty chemicals company reported $0.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.32 by $0.08. Chemours had a net margin of 1.34% and a return on equity of 29.48%. The company had revenue of $1.50 billion for the quarter, compared to analysts’ expectations of $1.44 billion. During the same period last year, the company earned $0.64 EPS. The firm’s revenue for the quarter was up .9% compared to the same quarter last year.

Chemours Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, December 16th. Shareholders of record on Friday, November 15th were paid a dividend of $0.25 per share. This represents a $1.00 dividend on an annualized basis and a dividend yield of 5.15%. The ex-dividend date was Friday, November 15th. Chemours’s dividend payout ratio is presently 200.00%.

Insider Transactions at Chemours

In other news, SVP Alvenia Scarborough sold 7,500 shares of Chemours stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $20.64, for a total transaction of $154,800.00. Following the sale, the senior vice president now owns 16,645 shares in the company, valued at $343,552.80. This trade represents a 31.06 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 0.47% of the company’s stock.

Institutional Investors Weigh In On Chemours

A number of large investors have recently added to or reduced their stakes in the company. Appian Way Asset Management LP purchased a new position in Chemours in the 3rd quarter valued at about $34,151,000. Vision One Management Partners LP acquired a new position in shares of Chemours in the third quarter worth about $28,252,000. Marshall Wace LLP boosted its holdings in Chemours by 23.8% in the second quarter. Marshall Wace LLP now owns 7,009,868 shares of the specialty chemicals company’s stock valued at $158,213,000 after purchasing an additional 1,347,710 shares during the last quarter. Khrom Capital Management LLC grew its stake in Chemours by 54.6% during the 2nd quarter. Khrom Capital Management LLC now owns 3,456,626 shares of the specialty chemicals company’s stock valued at $78,016,000 after purchasing an additional 1,220,967 shares in the last quarter. Finally, Scopia Capital Management LP acquired a new stake in Chemours during the 3rd quarter valued at approximately $13,623,000. 76.26% of the stock is owned by institutional investors and hedge funds.

Chemours Company Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.